NASDAQ:GLYC GlycoMimetics (GLYC) Stock Forecast, Price & News $1.90 -0.02 (-1.04%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$1.85▼$1.9650-Day Range$1.21▼$2.0852-Week Range$0.51▼$4.16Volume185,941 shsAverage Volume960,645 shsMarket Capitalization$122.08 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability GlycoMimetics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside321.1% Upside$8.00 Price TargetShort InterestHealthy2.05% of Shares Sold ShortDividend StrengthN/ASustainability-0.55Upright™ Environmental ScoreNews Sentiment0.00Based on 2 Articles This WeekInsider TradingAcquiring Shares$67,995 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.74) to ($0.76) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.16 out of 5 starsMedical Sector385th out of 983 stocksPharmaceutical Preparations Industry183rd out of 486 stocks 3.5 Analyst's Opinion Consensus RatingGlycoMimetics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, GlycoMimetics has a forecasted upside of 321.1% from its current price of $1.90.Amount of Analyst CoverageGlycoMimetics has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.05% of the outstanding shares of GlycoMimetics have been sold short.Short Interest Ratio / Days to CoverGlycoMimetics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GlycoMimetics has recently decreased by 2.22%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldGlycoMimetics does not currently pay a dividend.Dividend GrowthGlycoMimetics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGlycoMimetics has received a 73.56% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for GlycoMimetics is -0.55. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for GlycoMimetics this week, compared to 2 articles on an average week.Search InterestOnly 7 people have searched for GLYC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added GlycoMimetics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GlycoMimetics insiders have bought 842.41% more of their company's stock than they have sold. Specifically, they have bought $67,995.00 in company stock and sold $7,215.00 in company stock.Percentage Held by InsidersOnly 8.00% of the stock of GlycoMimetics is held by insiders.Percentage Held by Institutions49.50% of the stock of GlycoMimetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for GlycoMimetics are expected to decrease in the coming year, from ($0.74) to ($0.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GlycoMimetics is -2.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GlycoMimetics is -2.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGlycoMimetics has a P/B Ratio of 1.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About GlycoMimetics (NASDAQ:GLYC) StockGlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.Read More Receive GLYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter. Email Address GLYC Stock News HeadlinesMay 31, 2023 | finance.yahoo.comGlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare ConferenceMay 30, 2023 | msn.comGlycoMimetics: Insider Buying Continues, And Chart Looks HealthyJune 3, 2023 | Stocks To Trade (Ad)15 A.I. Trading Opportunities a DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 16, 2023 | finance.yahoo.comretail investors who own 36% along with institutions invested in GlycoMimetics, Inc. (NASDAQ:GLYC) saw increase in their holdings value last weekMay 13, 2023 | americanbankingnews.comInsider Buying: GlycoMimetics, Inc. (NASDAQ:GLYC) Director Acquires 30,000 Shares of StockMay 12, 2023 | seekingalpha.comGlycoMimetics: An Asymmetric Opportunity That Could Change HematologyMay 11, 2023 | americanbankingnews.comGlycoMimetics, Inc. (NASDAQ:GLYC) SVP Bruce S. Johnson Purchases 13,500 SharesMay 9, 2023 | americanbankingnews.comHC Wainwright Analysts Lower Earnings Estimates for GlycoMimetics, Inc. (NASDAQ:GLYC)June 3, 2023 | Stocks To Trade (Ad)15 A.I. Trading Opportunities a DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 4, 2023 | finance.yahoo.comQ1 2023 GlycoMimetics Inc Earnings CallMay 3, 2023 | finance.yahoo.comGlycoMimetics Reports Highlights and Financial Results for First Quarter 2023April 26, 2023 | finance.yahoo.comGlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023April 19, 2023 | finance.yahoo.comPossible turnaround for GlycoMimetics, Inc. (NASDAQ:GLYC) insiders, still down US$63k after a US$732k shopping spreeApril 4, 2023 | americanbankingnews.comGlycoMimetics, Inc. (NASDAQ:GLYC) Expected to Earn Q1 2023 Earnings of ($0.17) Per ShareApril 4, 2023 | americanbankingnews.comHC Wainwright Comments on GlycoMimetics, Inc.'s Q1 2023 Earnings (NASDAQ:GLYC)April 2, 2023 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for GlycoMimetics (NASDAQ:GLYC)March 31, 2023 | finance.yahoo.comGlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2022 Earnings Call TranscriptMarch 28, 2023 | americanbankingnews.comGlycoMimetics (GLYC) Scheduled to Post Quarterly Earnings on WednesdayMarch 25, 2023 | americanbankingnews.comGlycoMimetics (NASDAQ:GLYC) Lowered to "Sell" at StockNews.comMarch 17, 2023 | finance.yahoo.comGlycoMimetics, Inc. (GLYC) Interactive Stock Chart - Yahoo FinanceMarch 16, 2023 | finance.yahoo.comGlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023March 5, 2023 | uk.finance.yahoo.comGlycoMimetics, Inc. (GLYC) stock price, news, quote & history – Yahoo FinanceMarch 1, 2023 | finance.yahoo.comGlycoMimetics to Participate in Upcoming Cowen 43rd Annual Health Care ConferenceFebruary 21, 2023 | marketwatch.comSickle Cell Anemia Therapeutics Market by Top Manufacturers, Growing Demand and Supply 2023-2028February 15, 2023 | finance.yahoo.comGlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring CommitteeJanuary 22, 2023 | finance.yahoo.comGlycoMimetics, Inc.'s (NASDAQ:GLYC) Shift From Loss To ProfitJanuary 22, 2023 | finance.yahoo.comThis Small Pharma Company Could Develop Into a Nice TradeSee More Headlines GLYC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GLYC Company Calendar Last Earnings3/29/2023Today6/03/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GLYC CUSIPN/A CIK1253689 Webwww.glycomimetics.com Phone(240) 243-1201Fax301-738-2137Employees52Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.00 High Stock Price Forecast$8.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+321.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,690,000.00 Net MarginsN/A Pretax Margin-56,526.67% Return on Equity-81.16% Return on Assets-70.15% Debt Debt-to-Equity RatioN/A Current Ratio10.10 Quick Ratio10.10 Sales & Book Value Annual Sales$80,000.00 Price / Sales1,525.94 Cash FlowN/A Price / Cash FlowN/A Book Value$0.97 per share Price / Book1.96Miscellaneous Outstanding Shares64,250,000Free Float59,106,000Market Cap$122.08 million OptionableOptionable Beta2.10 Key ExecutivesHarout SemerjianPresident, Chief Executive Officer & DirectorBrian M. HahnChief Financial Officer & Senior Vice PresidentDeepak TiwariVice President-Technical OperationsEdwin P. RockChief Medical Officer & Senior Vice PresidentBruce JohnsonChief Commercial Officer & Senior Vice PresidentKey CompetitorsAnnovis BioNYSE:ANVSAquestive TherapeuticsNASDAQ:AQSTAtossa TherapeuticsNASDAQ:ATOSPardes BiosciencesNASDAQ:PRDSAlaunos TherapeuticsNASDAQ:TCRTView All CompetitorsInsiders & InstitutionsBrian M HahnSold 3,700 sharesTotal: $7,215.00 ($1.95/share)State Street CorpBought 30,200 shares on 5/16/2023Ownership: 0.291%Susquehanna International Group LLPBought 22,500 shares on 5/16/2023Ownership: 0.000%Two Sigma Investments LPBought 152,206 shares on 5/15/2023Ownership: 0.577%Affinity Asset Advisors LLCBought 300,000 shares on 5/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions GLYC Stock - Frequently Asked Questions Should I buy or sell GlycoMimetics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GLYC shares. View GLYC analyst ratings or view top-rated stocks. What is GlycoMimetics' stock price forecast for 2023? 1 Wall Street research analysts have issued 1 year target prices for GlycoMimetics' stock. Their GLYC share price forecasts range from $8.00 to $8.00. On average, they anticipate the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 321.1% from the stock's current price. View analysts price targets for GLYC or view top-rated stocks among Wall Street analysts. How have GLYC shares performed in 2023? GlycoMimetics' stock was trading at $3.03 at the beginning of the year. Since then, GLYC shares have decreased by 37.3% and is now trading at $1.90. View the best growth stocks for 2023 here. When is GlycoMimetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our GLYC earnings forecast. How were GlycoMimetics' earnings last quarter? GlycoMimetics, Inc. (NASDAQ:GLYC) released its quarterly earnings results on Wednesday, March, 29th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.02. What other stocks do shareholders of GlycoMimetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other GlycoMimetics investors own include Exelixis (EXEL), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), Cidara Therapeutics (cdtx), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Spectrum Pharmaceuticals (SPPI), Coherus BioSciences (CHRS), Verastem (VSTM) and Aldeyra Therapeutics (ALDX). What is GlycoMimetics' stock symbol? GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC." Who are GlycoMimetics' major shareholders? GlycoMimetics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include AXA S.A. (2.50%), Acadian Asset Management LLC (2.18%), BlackRock Inc. (1.01%), Two Sigma Advisers LP (0.93%), Two Sigma Investments LP (0.58%) and Affinity Asset Advisors LLC (0.00%). Insiders that own company stock include Brian M Hahn, Bruce S Johnson, Bvf Partners L P/Il, Daniel M Junius, Edwin Rock, John L Magnani, Patricia S Andrews, Public Equities LP Invus and Scott D Sandell. View institutional ownership trends. How do I buy shares of GlycoMimetics? Shares of GLYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is GlycoMimetics' stock price today? One share of GLYC stock can currently be purchased for approximately $1.90. How much money does GlycoMimetics make? GlycoMimetics (NASDAQ:GLYC) has a market capitalization of $122.08 million and generates $80,000.00 in revenue each year. The biotechnology company earns $-46,690,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis. How can I contact GlycoMimetics? GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The official website for the company is www.glycomimetics.com. The biotechnology company can be reached via phone at (240) 243-1201, via email at sannes@annesassociates.com, or via fax at 301-738-2137. This page (NASDAQ:GLYC) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlycoMimetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.